Amgen

Current directors and officers who also hold a role at another S&P 500 company.

• Charles M. HolleyCARR · DirectorPSX · Director
• Ellen Jamison KullmanDELL · DirectorGS · Director
• Wanda M. AustinAAPL · DirectorCVX · Director
• Amy E. MilesCARR · Director
• Robert A. BradwayBA · Director
• Robert EckertUBER · Director
• Tyler JacksTMO · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Oct 27, 2026

   (d) Election of Directors. On October 26, 2026, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed David W. Gibbs as a director of the Company, effective immediately. Mr. Gibbs served as Chief Executive Officer of Yum! Brands, Inc., a leading global restaurant company, from 2020 to September 2025 and as a director of Yum! Brands from 2019 to September 2025. Since October 2025, Mr. Gibbs has served as an advisor to Yum! Brands. Previously, he served as President and Chief Operating Officer of Yum! Brands from August 2019 to December 2019; President, Chief Operating Officer and Chief Financial Officer from January 2019 to August 2019; and President and Chief Financial Officer from 2016 to 2018. Earlier in his career at Yum! Brands, Mr. Gibbs served as Chief Executive Officer of the Pizza Hut Division from 2015 to 2016, President of Pizza Hut U.S.

   Read the 8-K filing
2. May 19, 2026

   Retirement of Peter H. Griffith, Chief Financial Officer On May 19, 2026, Amgen Inc. (the “Company”) publicly announced that Peter H. Griffith will retire from the role of the Company’s Executive Vice President and Chief Financial Officer, effective August 31, 2026. In connection with the transition of his role, Mr. Griffith will remain employed as an Executive Vice President, a non-executive officer position from September 1, 2026 until January 31, 2027. Mr. Griffith is currently retirement eligible under the Company’s plans and policies, and thus upon his departure in January 2027 will receive the retirement benefits provided by the Company’s plans and policies, described in the Company’s filings, including the Company’s proxy statement. Appointment of Thomas Dittrich, Executive Vice President and Chief Financial Officer In connection with Mr.

   Read the 8-K filing
3. Apr 22, 2026

   On April 22, 2026, Amgen Inc. (the “Company”) publicly announced that David M. Reese is retiring from the role of the Company’s Executive Vice President and Chief Technology Officer. To facilitate the further integration of our science, technology and data and build on the strong alignment of our commercial, medical and policy teams, the responsibilities of this role will be redistributed to James E. Bradner, Executive Vice President, Research and Development, Artificial Intelligence and Data, Murdo Gordon, Executive Vice President, Amgen Global Markets and Policy, and Peter H. Griffith, Executive Vice President and Chief Financial Officer, each effective as of June 1, 2026. Dr. Reese will remain employed as an Executive Vice President until his retirement on June 30, 2026. Departure of Executive Vice President On June 30, 2026, Dr.

   Read the 8-K filing
4. Jun 3, 2024

   The Board of Directors of Amgen Inc. (the “ Company ”) previously adopted, subject to stockholder approval, the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the “ Amended Plan ”), which amends and restates the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. The Amended Plan was approved by the Company’s stockholders on May 31, 2024 at the Company’s 2024 Annual Meeting of Stockholders (the “ Annual Meeting ”), as described below.

   Read the 8-K filing
5. Dec 14, 2023

   David M. Reese, M.D., will transition from Executive Vice President, Research and Development to Executive Vice President and Chief Technology Officer, a newly created executive officer position, responsible for accelerating the use of technology and artificial intelligence (AI) across all facets of Amgen Inc. (“Amgen” or the “Company”). James Bradner, M.D., has been hired as the Company’s Executive Vice President, Research and Development, and Chief Scientific Officer, an executive officer position. Dr. Bradner previously served as President of the Novartis Institutes for BioMedical Research, where he was a member of the Executive Committee of Novartis. These appointments are effective as of December 18, 2023 and both Dr. Reese and Dr. Bradner will report to Robert A. Bradway, Chairman and Chief Executive Officer of Amgen.

   Read the 8-K filing
6. Aug 4, 2023

   (b) and (c). On August 1, 2023, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed Matthew C. Busch, age 49, to serve as the Company’s Vice President, Finance and Chief Accounting Officer (“CAO”), effective August 14, 2023. Mr. Busch will be the Company’s principal accounting officer; he will not be an executive officer of the Company. Linda H. Louie, the Company’s current CAO, has served in this role since July 2020, and effective August 14, 2023, as part of the Company’s leadership development activities, Ms. Louie will move to the role of the Company’s Vice President, Finance, with responsibility for corporate financial planning and analysis, and will step down as the Company’s Chief Accounting Officer. Mr. Busch has served as the Company’s Vice President, Finance since August 2021. From 2020 until August 2021, Mr.

   Read the 8-K filing
7. Aug 3, 2022

   (d) Election of Directors. On August 3, 2022, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed Michael V. Drake as a director of the Company, effective immediately. Dr. Drake is the President of the University of California, having served in this position since August 2020. Prior to this, Dr. Drake was President of The Ohio State University from 2014 to June 2020. From 2005 to 2014, Dr. Drake was Chancellor of the University of California, Irvine and also a Distinguished Professor of Ophthalmology (School of Medicine) and Education (School of Education). Dr. Drake will serve as a member of the Board’s Corporate Responsibility and Compliance Committee and its Governance and Nominating Committee. Following the appointment of Dr. Drake, the Board will be composed of 13 directors, 12 of whom are independent. There are no transactions between Dr.

   Read the 8-K filing
8. Jul 30, 2021

   (d) Election of Directors. On July 29, 2021, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed S. Omar Ishrak as a director of the Company, effective immediately. Dr. Ishrak is the former Executive Chairman and Chairman of the Board of Directors of Medtronic plc, a global medical technology company. Dr. Ishrak served as Executive Chairman from April 2020, and Chairman of Medtronic from 2011 to December 2020. Dr. Ishrak served as the Chief Executive Officer of Medtronic from 2011 to April 2020. Prior to joining Medtronic, Dr. Ishrak served as President and Chief Executive Officer of GE Healthcare Systems, a provider of medical imaging and diagnostic technology and a division of GE Healthcare, from 2009 to 2011. Dr.

   Read the 8-K filing
9. Jul 23, 2020

   (d) Election of Directors. On July 22, 2020, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed Amy E. Miles as a director of the Company, effective July 23, 2020. Ms. Miles is the former Chair of the Board (from March 2015 to March 2018) and Chief Executive Officer (from June 2009 to March 2018) of Regal Entertainment Group, Inc. Ms. Miles also served as Chief Executive Officer of Regal Cinemas, Inc. from June 2009 to March 2018. Prior to this, Ms. Miles served as Executive Vice President, Chief Financial Officer and Treasurer, Regal Entertainment Group from 2002 to 2009. She also served as the Executive Vice President, Chief Financial Officer and Treasurer of Regal Cinemas from 2000 to 2009. Ms. Miles joined Regal Cinemas in 1999 as Senior Vice President of Finance. Previously, Ms. Miles was with Deloitte & Touche, LLP and PricewaterhouseCoopers LLP. Ms.

   Read the 8-K filing
10. Jul 23, 2020

    On July 23, 2020, the Board of Directors of Amgen Inc. (the “Company”) appointed Linda H. Louie, age 48, to serve as the Company’s Vice President, Finance and Chief Accounting Officer (“CAO”), effective immediately. Ms. Louie will be the Company’s principal accounting officer; she will not be an executive officer of the Company. Ms. Louie previously served as the Company’s Executive Director, Accounting since June 2015 and was a Director of Finance at the Company from April 2011 to June 2015. From June 2000 until April 2011, Ms. Louie progressed through various positions of increasing responsibility at the Company. She is a Certified Public Accountant and received her Master of Business Administration from the Fuqua School of Business at Duke University. In connection with the appointment of Ms.

    Read the 8-K filing
11. Oct 23, 2019

    On October 22, 2019, Amgen Inc. (the “Company”) publicly announced the appointment of Peter H. Griffith, age 60, to serve as the Company’s Executive Vice President and Chief Financial Officer, effective as of January 1, 2020. In the meantime, Mr. Griffith joins the Company as an Executive Vice President, Finance (a non-executive officer position) effective as of October 23, 2019 (his “Hire Date”). In connection with the appointment of Mr. Griffith, David W. Meline, age 61, will no longer serve as Executive Vice President and Chief Financial Officer as of the end of the day on December 31, 2019, but will continue as a non-executive officer to facilitate the transition. (c) Appointment of Chief Financial Officer On October 22, 2019, the Board of Directors of the Company (the “Board”) appointed Mr.

    Read the 8-K filing
12. Jul 26, 2018

    On July 26, 2018, Amgen Inc. (the “Company”) publicly announced that Sean E. Harper is retiring from the role of the Company’s Executive Vice President, Research and Development, and David M. Reese, the Company’s current Senior Vice President, Translational Sciences and Oncology, has been appointed by the Company’s Board of Directors (the “Board”) to serve as Executive Vice President, Research and Development, each effective as of July 26, 2018. The Company also announced that Anthony C. Hooper is retiring from the role of the Company’s Executive Vice President, Global Commercial Operations, and Murdo Gordon, Chief Commercial Officer of Bristol-Myers Squibb Company, has been appointed by the Company’s Board to serve as Executive Vice President, Global Commercial Operations, each effective as of September 3, 2018.

    Read the 8-K filing
13. Oct 24, 2017

    (d) Election of Directors. On October 24, 2017, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed Wanda M. Austin as a director of the Company, effective upon the December Board and committee meetings. Dr. Austin is the retired president and chief executive officer of The Aerospace Corporation, a leading architect of the United States’ national security space programs, where she served from 2008 until her retirement in 2016. From 2004 to 2007, Dr. Austin was senior vice president, National Systems Group of The Aerospace Corporation. Dr. Austin joined The Aerospace Corporation in 1979 and served in various positions from 1979 until 2004. Dr. Austin has served as an Adjunct Research Professor at the University of Southern California’s Viterbi School of Engineering since 2007.

    Read the 8-K filing
14. May 22, 2017

    (b) On May 19, 2017, the Company appointed Annette L. Such, Vice President, Finance and Chief Accounting Officer of Amgen Inc. (the “Company”), to serve as Vice President and Chief Audit Executive, effective upon the filing of the Company’s second quarter 2017 Form 10-Q with the Securities and Exchange Commission (the “Form 10-Q”). Therefore, upon the filing of such Form 10-Q, Ms. Such will step down as the Company’s Chief Accounting Officer and will no longer serve as the Company’s principal accounting officer. In connection with this change, David W. Meline, the Company’s Executive Vice President and Chief Financial Officer, in addition to his other roles, will act as the Company’s principal accounting officer until such time as a new Chief Accounting Officer is appointed.

    Read the 8-K filing
15. Feb 3, 2017

    (d) Election of Directors. On February 1, 2017, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed Charles M. Holley Jr. as a director of the Company. Mr. Holley is the former Executive Vice President and Chief Financial Officer for Wal-Mart Stores, Inc. (“Walmart”) where he served from November 2010 to December 2015 and as Executive Vice President between January 1, 2016 and January 31, 2016. Prior to this, Mr. Holley served as Executive Vice President, Finance and Treasurer of Walmart from 2007 to November 2010. From December 2005 through December 2006, he served as Senior Vice President. Prior to that, Mr. Holley was Senior Vice President and Controller from 2003 to 2005. Mr. Holley served various roles in Wal-Mart International from 1994 through 2002. Prior to this, Mr. Holley served in various roles at Tandy Corporation.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.